Beam Therapeutics

IPO

Breaking new ground to advance science with the potential to change lives

Public · Cambridge, United States · Founded 2017 · $528.0M raised

Employees
201–500
Founded
2017
Business Model
B2B
Website
beamtx.com
Total Funding
$528.0M
Last Round
$100.0M Growth EquityFeb 2026
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Beam Therapeutics is a clinical-stage biotech company pioneering base editing technology to develop precision genetic medicines. Their platform uses proprietary base editors delivered via nonviral, electroporation, and viral modalities to correct disease-causing mutations in DNA. The company's pipeline targets serious diseases including sickle cell disease, phenylketonuria, and alpha-1 antitrypsin deficiency.

Summary

Beam Therapeutics is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $528.0M in total across 4 rounds, most recently a $100.0M Growth Equity round in Feb 2026. Investors include F-Prime Capital, ARCH Venture Partners and Sixth Street.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Growth EquityGrowth EquityFeb 2026
$100.0M

Sign up to see all 5 events

Funding: Series A through Growth Equity. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Beam Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/beam-therapeutics"><img src="https://indexed.vc/api/badge/company/beam-therapeutics" alt="Beam Therapeutics on Indexed.vc" width="260" height="76" /></a>